No, she should not receive the third dose now
A 35-year-old woman who received two doses of HPV vaccine as a teenager is beyond the age for which catch-up vaccination is recommended and should not receive the third dose. The vaccine is not licensed for routine catch-up vaccination beyond age 26 years, and the evidence shows minimal population benefit in this age group due to likely prior HPV exposure 1, 2.
Age-Based Licensing and Recommendations
The quadrivalent HPV vaccine that was available when this patient was a teenager was not licensed for use in females aged >26 years 1. While newer formulations are now licensed through age 45, the 2019 ACIP guidelines explicitly state that catch-up HPV vaccination is not recommended for all adults aged >26 years 2.
Why Vaccination After Age 26 Is Not Recommended
The rationale is straightforward:
- HPV acquisition typically occurs soon after first sexual activity, making vaccine effectiveness substantially lower in older age groups due to prior infections 2
- By age 35, most sexually active individuals have already been exposed to one or more vaccine-type HPV strains
- The vaccine does not treat existing infections or prevent progression of established HPV disease—it only prevents new infections 2
- Population benefit is minimal in this age group, even though the vaccine remains safe 2
The Interrupted Series Exception Does Not Apply Here
While ACIP guidelines state that interrupted vaccine schedules can be completed without restarting the series, this guidance applies to individuals within the recommended age range (ages 9-26 years) 1. The key phrase is: "If only the third dose is delayed, it should be administered as soon as possible" 1—but this was written in the context of catch-up vaccination through age 26.
Shared Clinical Decision-Making (Ages 27-45)
The 2019 ACIP update introduced shared clinical decision-making for adults aged 27-45 years who are not adequately vaccinated 2. However:
- The American Cancer Society explicitly does not endorse this recommendation due to low effectiveness, low cancer prevention potential, and burden of decision-making 3
- This approach is intended for adults who might benefit from vaccination (e.g., those with new sexual partners or limited prior HPV exposure)
- At age 35, having received two doses as a teenager, the patient has already received substantial protection against the most common vaccine-type HPV strains she would have encountered
What Protection Does She Already Have?
Two doses received during adolescence likely provided significant protection:
- Recent evidence shows that two doses initiated before age 15 have comparable effectiveness to three doses against high-grade cervical lesions 4
- The immune response is strongest when vaccination occurs before age 15 4
- Even incomplete series provide partial protection against vaccine-type HPV strains not yet encountered
Clinical Bottom Line
Focus on cervical cancer screening, not completing the vaccine series. Cervical cancer screening recommendations do not change based on vaccination status 1. She should follow age-appropriate screening guidelines (typically co-testing with Pap and HPV testing every 5 years, or Pap alone every 3 years, depending on current guidelines).
Common Pitfall to Avoid
Do not conflate the guidance about completing interrupted series with age-based licensing restrictions. The interrupted schedule guidance was written for individuals still within the catch-up vaccination window (through age 26), not for adults in their mid-30s.